

HR 7722

Matt's Act

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Jul 22, 2020

Current Status: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Education and

Latest Action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (Jul 22, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/7722>

Sponsor

Name: Rep. Fortenberry, Jeff [R-NE-1]

Party: Republican • **State:** NE • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Craig, Angie [D-MN-2]	D · MN		Jul 22, 2020

Committee Activity

Committee	Chamber	Activity	Date
Education and Workforce Committee	House	Referred To	Jul 22, 2020
Energy and Commerce Committee	House	Referred To	Jul 22, 2020

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Jul 22, 2020)

Matt's Act

This bill limits the amount that private health insurance plans may charge plan holders for insulin drugs to a maximum of \$20, or \$0 for high deductible plans; pharmacies may charge an uninsured individual who has diabetes the average net price of such drugs after deducting any rebates and discounts provided by drug manufacturers, plus limited additional charges for distributing and dispensing costs.

Actions Timeline

- **Jul 22, 2020:** Introduced in House
- **Jul 22, 2020:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.